Lisette Kimbere
Adult Health · New York, NYNPI 1851720551
Payments from drug & device makers
Across 152 payments — averaging $63.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$2K
- E.r. Squibb & Sons, L.L.C.$837
- Johnson & Johnson$618
- Novartis$547
- Amgen$516
- Stemline Therapeutics Inc.$434
- plus $5K from 31 others
What the payments were for
- Consulting fees$1,36014%
- Travel & lodging$70%
- Food & beverage$7,98883%
- Education$3003%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 10 | $1,745 |
| E.r. Squibb & Sons, L.L.C. | 7 | $837 |
| Johnson & Johnson | 7 | $618 |
| Novartis | 26 | $547 |
| Amgen | 7 | $516 |
| Stemline Therapeutics Inc. | 9 | $434 |
| EMD Serono, Inc. | 6 | $373 |
| Jazz Pharmaceuticals Inc. | 12 | $367 |
| Incyte Corporation | 4 | $363 |
| Merck | 15 | $357 |
| Rigel Pharmaceuticals, Inc. | 10 | $353 |
| AstraZeneca(2 entities) | 3 | $264 |
| Janssen Scientific Affairs, LLC | 1 | $250 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $239 |
| Gilead | 2 | $238 |
| Seagen Inc. | 3 | $216 |
| Novocure Inc. | 1 | $213 |
| Coherus Oncology, Inc. | 1 | $150 |
| Legend Biotech USA Inc. | 1 | $149 |
| Genmab U.S., Inc. | 2 | $144 |
| Madrigal Pharmaceuticals | 1 | $135 |
| Exelixis Inc. | 1 | $125 |
| Sanofi-aventis U.S. LLC | 1 | $125 |
| GSK | 1 | $125 |
| Springworks Therapeutics, Inc. | 1 | $124 |
| Regeneron Healthcare Solutions, Inc. | 1 | $121 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $119 |
| Bayer | 2 | $117 |
| Bristol Myers Squibb | 4 | $80 |
| Daiichi Sankyo Inc. | 2 | $50 |
| Immunocore Limited | 1 | $31 |
| Melinta Therapeutics, LLC | 1 | $24 |
| Puma Biotechnology, Inc. | 1 | $22 |
| Caris MPI, Inc. | 1 | $22 |
| Chiesi USA, Inc. | 1 | $22 |
| Syndax Pharmaceuticals, Inc. | 1 | $21 |
| Sanofi | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,655 in reported general payments places this provider in the 95th percentile of 3,828 adult health providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TasignaNilotinib Hcl | 15 | $301,479 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisTasigna | $547 | $301,47915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,828 adult health providers in New York.
Other adult health in New York
- Marguerite CallahanNew York$1.4M
- Donna CatameroNew York$279K
- Alyson HartyNew York$65K
- Laura GraaflandNew York$51K
- Allysa SaggeseNew York$49K
- Juliet EscalonNew York$46K
- Teshmanie RampersaudNew York$23K
- Jenna WenzelNew York$22K
- Elizabeth SavageNew York$20K
- Libby LevineNew York$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.